Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon Mar 08, 2022 1:14pm
200 Views
Post# 34496092

RE:Exactly what we want to hear ...

RE:Exactly what we want to hear ...So ... if there is a link between the gut and dementia, makes sense that we should be able to find a link between IBD and dementia.

June 23, 2020
BMJ - Inflammatory Bowl Disease Linked to Doubling of Dementia Risk

https://www.bmj.com/company/newsroom/inflammatory-bowel-disease-linked-to-doubling-in-dementia-risk/

Which also means if inflammation in the gut leads to neuro-inflammation ... what damage is the neuro-inflammation doing to the SCN and to our circadian rhythm ?

The SCN regulates numerous cellular processes in our circadian system including ... cognition, immune response, cellular metabolism, epigenetic modifications, cell cycle, redox hemostisis and gut microbiota.

https://theconversation.com/alzheimers-disease-linked-to-circadian-rhythm-new-research-in-mice-177090

So ... just maybe ... gut affects the brain ... brain affects the gut ... and we have an uncontrollable downward spiral in health due to uncontrolled inflammation (gut/brain).  As we age, the problem is likely worse.

-------------------

Improve gut health via better medications for pain to replace NSAIDs.
Then take care of IBD to further improve gut health.
Is this order of development only by coincidence or for an underlying purpose?
Hmmmmmmmmm.

: )
<< Previous
Bullboard Posts
Next >>